EUCTR2019-004540-29-CZ进行中（未招募）1 期
Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia - Pona-CE
Ústav hematologie a krevní transfuze0 个研究点目标入组 32 人开始时间: 2020年7月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with newly diagnosed, previously untreated, Ph-positive [either t(9;22) and/or BCR-ABL positive] B-precursor acute lymphoblastic leukemia;
- •Age 18-65 years;
- •Eligible to intensive chemotherapy, due to general health status;
- •ECOG performance status =2;
- •Absence of significant liver disease, as defined by the following criteria: total serum bilirubin =1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, alanine aminotransferase (ALT) =2.5 × ULN or =5 x ULN if leukemic involvement of the liver is present, and aspartate aminotransferase (AST) =2.5 × ULN or =5 x ULN if leukemic involvement of the liver is present;
- •Adequate pancreatic function as defined by serum amylase and lipase =1.5 × ULN;
- •Diagnostic sample of bone marrow (or peripheral blood with >50% of blasts) available for central MRD assessment;
- •Subject has provided written informed consent prior to any screening procedure.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Lymphoid blast crisis of CML;
- •Active serious infection not controlled by oral or intravenous antibiotics;
- •Active known HBV or HCV hepatitis or positive HIV serology;
- •History of acute pancreatitis within 1 year of study or history of chronic pancreatitis;
- •Uncontrolled hypertriglyceridemia (triglycerides >5.1 µmol/L);
- •Clinically significant, uncontrolled or active cardiovascular disease, specifically including, but not restricted to: any history of myocardial infarction, stroke, or revascularization; unstable angina or transient ischemic attack within 6 months prior to enrolment; congestive heart failure within 6 months prior to enrolment or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards; history of clinically significant (as determined by the treating physician) atrial arrhythmia; any history of ventricular arrhythmia; any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism;
- •Uncontrolled hypertension (diastolic blood pressure >90 mmHg; systolic >140 mmHg). Patients with hypertension should be under treatment on study entry to effect blood pressure control;
- •Creatinine levels > 160 µmol/L or estimated creatinine clearance of<50 mL/min;
- •GI disease and/or major GI surgery that may significantly alter the absorption of study drug;
- •Hypersensitivity to the active substance or to any of the excipients, especially galactose intolerance;
- •Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib (see chapter 4.5 of Iclusig SPC attached to the protocol)
- •Female patients who are pregnant or breast feeding or patients of childbearing potential not willing to use a highly effective method of contraception during the study and for 3 months following the last dose of study drug;
- •Male patients whose sexual partner(s) are women of childbearing potential who are not willing to use a highly effective method of contraception, one of which includes a condom, during the study;
- •Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention;
- •Any concurrent severe and/or uncontrolled medical condition, which could, in the opinion of the investigator, compromise participation in the study;
- •Concurrent participation in another clinical study with an investigational medical product.
研究者
相似试验
招募中
1 期
The study's aim is to treat adult patients affected by Ph-like ALL, a Philadelphianegative ALL subtype, with a combination of the tyrosine kinase inhibitor ponatinib and chemotherapy. The main objective of the trial is to improve the percentace ofpatients that achieve a disease remission also at the molecular level.CTIS2023-510240-20-00Fondazione Gimema Franco Mandelli Onlus32
终止
2 期
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALLAcute Lymphoblastic Leukemia, AdultPh+ ALLNewly DiagnosedNCT04554459Institute of Hematology and Blood Transfusion, Czech Republic4
进行中（未招募）
2 期
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaNCT03147612M.D. Anderson Cancer Center22
进行中（未招募）
1 期
A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)Acute Myeloid Leukaemia (FLT3-ITD positive)Cancer - Leukaemia - Acute leukaemiaACTRN12614000810617Australasian Leukaemia and Lymphoma Group35
已完成
3 期
With Ponatinib on the track for treatment-free-remission in chronic myeloid leukaemiaC92.1Chronic myeloid leukaemia [CML], BCR/ABL-positiveDRKS00016363niversität Heidelberg17